1. 32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers. (April 2019) Authors: Litzenburger, Tobias; Müller, Fabian; Schultz, Armin; Klein, Elliott; Ramanujam, Meera; Wu, Jing; Wiebe, Sabrina; Benediktus, Ewald; Hui, Jianan; Li, Xiujiang; Flack, Mary; Padula, Steven J; Visvanathan, Sudha; Steffgen, Jürgen; Hünnemeyer, Andreas Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. Issue 4 (20th November 2020) Authors: Litzenburger, Tobias; Steffgen, Jürgen; Benediktus, Ewald; Müller, Fabian; Schultz, Armin; Klein, Elliott; Ramanujam, Meera; Harcken, Christian; Gupta, Alpana; Wu, Jing; Wiebe, Sabrina; Li, Xiujiang; Flack, Mary; Padula, Steven J.; Visvanathan, Sudha; Hünnemeyer, Andreas; Hui, Jianan Journal: British journal of clinical pharmacology Issue: Volume 87:Issue 4(2021) Page Start: 1824 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗